HLA B subtype analysis in patients developing tuberculosis during anti-TNF treatment
Makaleler > Tam Makale · 2025
Yazarlar: Fatih Albayrak, Gökhan KESER, Serdar Oztuzcu, Belkıs Nihan Coşkun, Yavuz Pehlivan, Tuba Demirci Yıldırım, Gökçe Kenar Artın, Gözde Çetin Yıldırım, Bünyamin Kısacık
Scientific Reports, Uluslararası, Wos, 2025, cilt 15, ss 15152-15152
DOI: 10.1038/s41598-025-00290-1
Özet
In this study, we aimed to evaluate HLA-B subtypes in cases developing TB while using anti-TNF agents and to compare with the HLA-B subtypes of three different groups including community-acquired TB cases, anti-TNF patients without TB and healthy controls. The study consisted of four groups. Group 1: 35 community-acquired TB patients, group 2; 47 anti-TNF-TB patients, group 3; 61 anti-TNF (non TB) patients and group 4; 40 healthy controls. HLA-B subgroups were studied genetically from blood samples taken from the patients. Approval was received from the ethics committee. HLA-B typing was performed by using the LIFECODES HLA-B eRES SSO Typing SSO typing kit (Immucor, Stamford, CT, USA). Among HLA-B subtypes, significant differences between the four groups were found only for HLA-B5, HLA-B8, HLA-B27 and HLA-B38. Although frequency of HLA-B8 was highest in patients developing TB during anti-TNF treatment, significance was lost after Bonferoni correction. HLA-B27 was significantly higher in both anti-TNF groups, with and without TB, due to presence of patients with ankylosing spondylitis in those groups. To our knowledge, this is the first study analyzing HLA-B subtypes in anti-TNF patients developing TB. Although in literature HLA-B8 positivity was suggested to associate with or to confer a risk for community-acquired TB, we could not confirm this association in anti-TNF patients developing TB. However, further studies with larger number of patients from different ethnic groups are clearly needed to get the final word in this topic.